Talasaz AmirAli sold $6.3M of GH (indirect holdings)

Talasaz AmirAli (Co-Chief Executive Officer) sold 37,500 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $169.16 ($168.20–$170.29, $6.34M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Talasaz AmirAli
Published Aug 24, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for Guardant Health.

02

Market read

First public disclosure of a sizable insider sale by Guardant Health's co‑CEO.

03

What to watch

Potential upcoming clinical data releases may offset any negative sentiment from the sale.

Relevance 6/10Novelty 7/10Timing: filed 2026-08-24, reflects same‑day insider activity

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Co-CEO Talasaz AmirAli sold 37,500 shares for $6.34M via open-market transactions on 2026-08-21.

Expected impact

Potential slight dip in GH price over the next few days.

Evidence & confidence

Insider sales by a top executive can be viewed as a negative signal, but the amount ($6.3M) is not material for a mid‑cap biotech.

Market effects

Minimal impact on broader biotech sector; similar insider sales are common.

None

Low

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Guardant Health, Inc.

    Biotech firm focused on liquid biopsy diagnostics.

  • Talasaz AmirAli

    Co-Chief Executive Officer of Guardant Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.